Milestone says heart disorder therapy under FDA review again

Grandbrothers/iStock Editorial via Getty Images

Milestone Pharmaceuticals (NASDAQ:MIST) announced on Friday that the U.S. FDA accepted for review its responses to the rejection letter sent early this year regarding its marketing application for its heart disease therapy Cardamyst (etripamil) nasal spray.

The Canadian biopharma's New